Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Pipeline Review, H2 2018
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'Phosphatidylinositol 4,5 Bisphosphate 3 Kinase - Pipeline Review, H2 2018'; Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) pipeline Target constitutes close to 22 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes.
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - The phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha also called p110? is a protein encoded by the PIK3CA gene. It is involved in cell growth, survival, proliferation, motility and morphology. It participates in cellular signaling in response to various growth factors. It is involved in the activation of AKT1 and signaling via insulin receptor substrate (IRS) proteins. It is essential in endothelial cell migration during vascular development through VEGFA signaling. It is required for lymphatic vasculature development.
The report 'Phosphatidylinositol 4,5 Bisphosphate 3 Kinase - Pipeline Review, H2 2018' outlays comprehensive information on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 10 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology and Infectious Disease which include indications Metastatic Breast Cancer, Breast Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Multiple Myeloma (Kahler Disease), Ovarian Cancer, Solid Tumor, Follicular Lymphoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Pancreatic Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Thyroid Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Thyroid Cancer, B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, CNS Lymphoma, Colon Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Lung Cancer, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Mantle Cell Lymphoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Myelofibrosis, Non-Small Cell Lung Carcinoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Ductal Adenocarcinoma, Papillary Thyroid Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary CNS Lymphoma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Squamous Cell Carcinoma, Thrombocythemia Myelofibrosis, Thymoma (Thymic Epithelial Tumor) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Phosphatidylinositol 4,5 Bisphosphate 3 Kinase - Pipeline Review, H2 2018'; Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) pipeline Target constitutes close to 22 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes.
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - The phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha also called p110? is a protein encoded by the PIK3CA gene. It is involved in cell growth, survival, proliferation, motility and morphology. It participates in cellular signaling in response to various growth factors. It is involved in the activation of AKT1 and signaling via insulin receptor substrate (IRS) proteins. It is essential in endothelial cell migration during vascular development through VEGFA signaling. It is required for lymphatic vasculature development.
The report 'Phosphatidylinositol 4,5 Bisphosphate 3 Kinase - Pipeline Review, H2 2018' outlays comprehensive information on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 10 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology and Infectious Disease which include indications Metastatic Breast Cancer, Breast Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Multiple Myeloma (Kahler Disease), Ovarian Cancer, Solid Tumor, Follicular Lymphoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Pancreatic Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Thyroid Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Thyroid Cancer, B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, CNS Lymphoma, Colon Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Lung Cancer, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Mantle Cell Lymphoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Myelofibrosis, Non-Small Cell Lung Carcinoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Ductal Adenocarcinoma, Papillary Thyroid Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary CNS Lymphoma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Squamous Cell Carcinoma, Thrombocythemia Myelofibrosis, Thymoma (Thymic Epithelial Tumor) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153)
- The report reviews Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics and enlists all their major and minor projects
- The report assesses Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Overview
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
AstraZeneca Plc
Bayer AG
Curis Inc
Eli Lilly and Co
Genentech Inc
Millennium Pharmaceuticals Inc
Novartis AG
Onconova Therapeutics Inc
PIQUR Therapeutics AG
Sphaera Pharma Pte Ltd
Yangtze River Pharmaceutical Group
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Drug Profiles
AL-58922 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alpelisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1082439 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimiralisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buparlisib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GDC-0077 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HHCYH-33 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3023414 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSC-765844 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ON-146040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PQR-514 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PQR-530 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
serabelisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-2523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PI3K Alpha for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pan PI3K for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PI3K Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PIK3CA and MTOR for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SN-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPR-965 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
taselisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Dormant Products
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Discontinued Products
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Product Development Milestones
Featured News & Press Releases
Aug 24, 2018: Novartis reports positive results from SOLAR-1 trial
Jul 30, 2018: Adlai Nortye announces the publication of the Biomarker Analysis from BERIL-1, the Buparlisib study in HNSCC
Jun 13, 2018: A medical first: CLOVES Syndrome and overgrowth syndromes: remarkable improvement in the health of 19 paediatric and adult patients using a new therapeutic strategy
Jun 02, 2018: Drug Combination Slows Growth of Most Common Type of Advanced Breast Cancer
May 31, 2018: Curis Announces FDA Fast Track Designation for Fimepinostat Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Dec 01, 2017: Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition
Nov 14, 2017: Novartis To Present Data On Alpelisib (BYL719) At Upcoming 40th annual San Antonio Breast Cancer Symposium (SABCS)
Sep 25, 2017: SignalRx Presents in silico Design of Dual PI3K/BRD4 Inhibitors for Combinatorial Activation of Anti-tumor Immunity in Treating Cancer
Sep 08, 2017: LORELEI: Taselisib Boosts Breast Tumor Shrinkage
May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting
May 01, 2017: SignalRx Discloses its Novel Immuno-Oncology Program Approach at the 12th Annual Drug Discovery Chemistry 2017 Meeting
Apr 27, 2017: PIQUR Receives EMA Orphan Drug Designation for PQR309 in Diffuse Large B-Cell Lymphoma
Feb 01, 2017: SignalRx Pharmaceuticals Announces Breakthrough Results on Novel Anti-Cancer Dual PI3K-BRD4 Inhibition Paradigm in PNAS Publication
Dec 12, 2016: PI3K Inhibitor Buparlisib in Combination with Fulvestrant Prolongs PFS Compared to Placebo Plus Fulvestrant
Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Overview
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
AstraZeneca Plc
Bayer AG
Curis Inc
Eli Lilly and Co
Genentech Inc
Millennium Pharmaceuticals Inc
Novartis AG
Onconova Therapeutics Inc
PIQUR Therapeutics AG
Sphaera Pharma Pte Ltd
Yangtze River Pharmaceutical Group
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Drug Profiles
AL-58922 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alpelisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1082439 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimiralisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buparlisib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GDC-0077 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HHCYH-33 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3023414 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSC-765844 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ON-146040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PQR-514 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PQR-530 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
serabelisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-2523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PI3K Alpha for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pan PI3K for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PI3K Alpha for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PIK3CA and MTOR for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SN-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPR-965 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
taselisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Dormant Products
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Discontinued Products
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) - Product Development Milestones
Featured News & Press Releases
Aug 24, 2018: Novartis reports positive results from SOLAR-1 trial
Jul 30, 2018: Adlai Nortye announces the publication of the Biomarker Analysis from BERIL-1, the Buparlisib study in HNSCC
Jun 13, 2018: A medical first: CLOVES Syndrome and overgrowth syndromes: remarkable improvement in the health of 19 paediatric and adult patients using a new therapeutic strategy
Jun 02, 2018: Drug Combination Slows Growth of Most Common Type of Advanced Breast Cancer
May 31, 2018: Curis Announces FDA Fast Track Designation for Fimepinostat Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Dec 01, 2017: Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition
Nov 14, 2017: Novartis To Present Data On Alpelisib (BYL719) At Upcoming 40th annual San Antonio Breast Cancer Symposium (SABCS)
Sep 25, 2017: SignalRx Presents in silico Design of Dual PI3K/BRD4 Inhibitors for Combinatorial Activation of Anti-tumor Immunity in Treating Cancer
Sep 08, 2017: LORELEI: Taselisib Boosts Breast Tumor Shrinkage
May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting
May 01, 2017: SignalRx Discloses its Novel Immuno-Oncology Program Approach at the 12th Annual Drug Discovery Chemistry 2017 Meeting
Apr 27, 2017: PIQUR Receives EMA Orphan Drug Designation for PQR309 in Diffuse Large B-Cell Lymphoma
Feb 01, 2017: SignalRx Pharmaceuticals Announces Breakthrough Results on Novel Anti-Cancer Dual PI3K-BRD4 Inhibition Paradigm in PNAS Publication
Dec 12, 2016: PI3K Inhibitor Buparlisib in Combination with Fulvestrant Prolongs PFS Compared to Placebo Plus Fulvestrant
Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Advenchen Laboratories LLC, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Bayer AG, H2 2018
Pipeline by Curis Inc, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Genentech Inc, H2 2018
Pipeline by Millennium Pharmaceuticals Inc, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Onconova Therapeutics Inc, H2 2018
Pipeline by PIQUR Therapeutics AG, H2 2018
Pipeline by Sphaera Pharma Pte Ltd, H2 2018
Pipeline by Yangtze River Pharmaceutical Group, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Discontinued Products, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Advenchen Laboratories LLC, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Bayer AG, H2 2018
Pipeline by Curis Inc, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Genentech Inc, H2 2018
Pipeline by Millennium Pharmaceuticals Inc, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Onconova Therapeutics Inc, H2 2018
Pipeline by PIQUR Therapeutics AG, H2 2018
Pipeline by Sphaera Pharma Pte Ltd, H2 2018
Pipeline by Yangtze River Pharmaceutical Group, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Discontinued Products, H2 2018 (Contd.1), H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Advenchen Laboratories LLC
AstraZeneca Plc
Bayer AG
Curis Inc
Eli Lilly and Co
Genentech Inc
Millennium Pharmaceuticals Inc
Novartis AG
Onconova Therapeutics Inc
PIQUR Therapeutics AG
Sphaera Pharma Pte Ltd
Yangtze River Pharmaceutical Group
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Advenchen Laboratories LLC
AstraZeneca Plc
Bayer AG
Curis Inc
Eli Lilly and Co
Genentech Inc
Millennium Pharmaceuticals Inc
Novartis AG
Onconova Therapeutics Inc
PIQUR Therapeutics AG
Sphaera Pharma Pte Ltd
Yangtze River Pharmaceutical Group
